ENRIQUE MARÍA
OCIO SAN MIGUEL
Investigador en el periodo 2013-2018
Complejo Asistencial de Segovia
Segovia, EspañaPublicaciones en colaboración con investigadores/as de Complejo Asistencial de Segovia (14)
2023
-
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Haematologica, Vol. 108, Núm. 10, pp. 2753-2763
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
2021
-
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852
-
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group
British Journal of Haematology, Vol. 192, Núm. 3, pp. 522-530
2017
-
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma
Haematologica, Vol. 102, Núm. 5, pp. 922-931
2016
-
Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma
Leukemia, Vol. 30, Núm. 10, pp. 2026-2031
2015
-
The cellular origin and malignant transformation of Waldenström macroglobulinemia
Blood, Vol. 125, Núm. 15, pp. 2370-2380
2014
2013
-
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Haematologica, Vol. 98, Núm. 1, pp. 79-86
-
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia
Leukemia, Vol. 27, Núm. 8, pp. 1722-1728
2012
-
Dasatinib as a bone-modifying agent: Anabolic and anti-resorptive effects
PLoS ONE, Vol. 7, Núm. 4
2011
-
The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis
Blood, Vol. 117, Núm. 13, pp. 3613-3616
2007
-
6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis
British Journal of Haematology, Vol. 136, Núm. 1, pp. 80-86
2003
-
Immunophenotypic analysis of Waldenstrom's macroglobulinemia
Seminars in Oncology, Vol. 30, Núm. 2, pp. 187-195